Deutsche Bank AG vs Teladoc Health Inc — how do they compare? Deutsche Bank AG trades at $33.69 (market cap $62.42B), while Teladoc Health Inc trades at $5.79 (market cap $1.01B). The key difference: Deutsche Bank AG is far larger — about 61.8× Teladoc Health Inc's market cap, and Deutsche Bank AG pays a 3.46% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Teladoc Health Inc for 39 Days on average.
| DB | TDOC | |
|---|---|---|
Market Cap | $62.42B | $1.01B |
Volume | 2,918,760 | 4,668,477 |
Sector | Financials | Health |
52-Week High | $41.56 | $9.72 |
52-Week Low | $28.37 | $4.47 |
Typical Hold Time | 80 Days | 39 Days |
Enterprise Value | $77.06B | $1.27B |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.58, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.09 and P/B of 0.71. Recent earnings show volatility with a Q2 2026 miss but strong Q1 2026 beat. The company demonstrates improved financial health with 2025 net cash flow of $7.61B and rising revenue trends from $30.0B in 2024 to $32.1B in 2025.
DB offers value investment potential with below-market valuations and positive cash flow generation, though technical weakness and mixed analyst sentiment (21% buy, 58% hold) suggest cautious optimism. Key risks include investment banking revenue volatility and significant workforce retirement challenges. The path to 2028 targets depends on wealth management growth and cost control execution.
Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.
TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →